170 filings
Page 2 of 9
8-K
z4sp25tv8yro
12 Apr 22
Other Events
4:07pm
8-K
5ttocfpp92kxf
12 Apr 22
Regulation FD Disclosure
9:00am
8-K
47rgaer7b
28 Feb 22
Humanigen Reports Year-End 2021 Financial Results
4:01pm
8-K
5xeayvwhse
5 Jan 22
Other Events
6:04am
8-K
w1f63g8l7du0
2 Dec 21
Other Events
8:00am
8-K
igl3t26 8rcyup
26 Nov 21
Departure of Directors or Certain Officers
5:00pm
8-K
cax7plviyvals80l
12 Nov 21
Results of Operations and Financial Condition
4:01pm
8-K
fdvxen35
9 Nov 21
Regulation FD Disclosure
8:00am
8-K
h2zw78hj9g6
20 Oct 21
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
9:13am
8-K
kzy8629
5 Oct 21
Departure of Directors or Certain Officers
4:05pm
8-K
o9hw6d2 gr
14 Sep 21
Regulation FD Disclosure
5:00pm
8-K
qgm7c
10 Sep 21
Other Events
6:01am
8-K
ip0eci woaqo3
12 Aug 21
Humanigen Reports Second Quarter 2021 Financial Results
4:01pm
8-K
c2pbkcdb92szbn
4 Aug 21
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
6:04am
8-K
vmkdpc8ta7c9u209crqx
14 Jul 21
Regulation FD Disclosure
11:58am
8-K
8d2 s2po62
21 Jun 21
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
g3dv dwm86zyjyjqa8ge
17 Jun 21
Humanigen 2021 Annual Stockholder Meeting June 17
6:30am
8-K
lkv4f6lpc6sxqw06 gz
28 May 21
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
5:00pm
8-K
ay1ja
13 May 21
Humanigen Reports First Quarter 2021 Financial Results
4:06pm
8-K
5sv0sgpw o0
20 Apr 21
Humanigen Reports Positive Data with Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
5:28pm